Pharma & Healthcare in Argentina: Turning a Corner?
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
Address: Escalada 1454, Buenos Aires (C1407LED),Argentina
Tel: (5411) 4670-3474
Web: http://www.dromex.com.ar/index_en.php
Dromex is a company founded on the basis of commitment and business loyalty between customers and suppliers in the Argentinian market. Dromex has over 25 years of experience in supplying active principles for the pharmaceutical industry, as well as a highly qualified, proactive and efficient professional work team to offer a high-class service.
Dromex’s main business is representing manufacturers of active principles for the Argentinean pharmaceutical industry. We represent first-class companies who work under the highest quality standards, recognized worldwide.
Having its own warehouse, authorized by the ANMAT (local regulatory agency), enables Dromex to keep the raw materials with the highest demand. Dromex can therefore offer a wide range of products and services to meet all the needs of any laboratory.
Dromex has a subsidiary in Brazil, Dromex Brasil, which carries out the same type of business in that market.
Warehousing, representing manufacturers
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
Gustavo Pelizzari leads Elea, Argentina’s largest pharmaceutical company by sales volume, employing 1,350 people. Under his leadership, Elea has achieved the unique distinction of simultaneously leading both the retail pharmaceutical…
Gala Díaz Langou, a senior analyst and executive director at Argentina’s premier think tank CIPPEC, assesses the country’s recent transformative journey under President Milei. Drawing on 25 years of institutional…
Keila Barral, founder of Cromodata, brings together a personal journey of resilience and a career in technology to address one of Latin America’s biggest healthcare challenges: fragmented patient data. After…
Argentina’s pharmaceutical industry combines a robust domestic manufacturing base with growing international reach and regulatory credibility. In this interview, Mauricio Claverí, Chief Economist at CILFA, explores how local companies are…
Juan Jose Marconi, Executive Director of Cooperala, offers a unique perspective shaped by decades of leadership across Argentina’s pharmaceutical and healthcare sectors. With a strong academic background in applied mathematics,…
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
See our Cookie Privacy Policy Here
